Novartis Asks CHMP To Modify European Galvus Label To Recommend Lower Dose
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients taking 50 mg dose of DPP-4 inhibitor had fewer liver enzyme elevations than those taking 100 mg, a profile Novartis wants to include in the label prior to EU launch.